Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: f
View:
• Documented history of oHCM with documented resting and/or Valsalva LVOT obstruction ≥ 50 mmHg who are currently receiving mavacamten commercially.
• Echo-derived LVEF ≥55% on mavacamten at the time of enrollment.
• Patient willing to consent for the study and undergo the study procedures.
Locations
United States
Missouri
St. Luke's Hospital - Mid America Heart Institute
NOT_YET_RECRUITING
Kansas City
Oregon
Oregon Health & Science University
RECRUITING
Portland
Contact Information
Primary
Ahmad Masri
masria@ohsu.edu
503-494-7551
Time Frame
Start Date: 2026-05-05
Estimated Completion Date: 2027-03-15
Participants
Target number of participants: 40
Treatments
Experimental: CMI
Switching from mavacamten on day 1 to aficamten starting at week 2.
Related Therapeutic Areas
Sponsors
Collaborators: Saint Lukes Hospital Mid America Heart Institute, Cytokinetics
Leads: Oregon Health and Science University